Given that lenvatinib plus anti-PD-1 antibody can enhance antitumor activity in HCC by decreasing tumor-associated macrophage 38, 39, targeting BEX4 may further improve the efficacy of the combination therapy. Here, BEX4 is linked to hepatocellular carcinoma.